Robin Harper Cowie: Yes, there is. So we have — still have some tenant improvement dollars that we expect to exhaust here in the third quarter, and then there’ll be some CapEx in third quarter and fourth quarter. We moved towards the end of — well, at the end of the year and will be live in the new laboratory facility for 2024. So we’re not performing tests in the new facility until the New Year. So we would expect to see sort of the consistent CapEx in third and fourth quarter like we’ve seen in first and second.
Kyle Mikson: So there wouldn’t be like a step up temporarily?
Robin Harper Cowie: No step up in the amount of CapEx, but a step down in the tenant improvement dollars that come in. So we’ll exhaust that here in the third quarter and then the final amount will be all out of pocket the CapEx.
Kyle Mikson: Interesting. Thanks Robin, thank you, Scott. Congrats guys.
Scott Hutton: Thank you, Kyle.
Operator: Thank you. Our last question comes from the line of Tejas Savant of Morgan Stanley. Your line is now open.
Yuko Oku: Hello, this is Yuko on the call for Tejas. Thank you for taking our question. Just following-up on some of the biopharma business comments here. Could you comment on how delays on prospective clinical trial enrollment and sample delivery has trended over the course of the quarter and into July? And also could you provide a degree of customer concentration for the $9.3 million under contract?
Scott Hutton: Hi Yuko. Thanks for the question. Yes, when we think about the trends, one of the things that we have found encouraging and we’re excited about is we have seen access to retrospective samples and prospective trial enrollment increase in pick up. And so we’ve been watching that closely over time and really been waiting for that. The nice thing about having the significant amount of dollars under contract that we have is knowing that it really comes back to access, timing, and cadence. And so we feel like there is movement and progress there, and that’s encouraging for us. We’ve also seen a record number of request for proposals moving forward and so we feel like we’re in a really, really strong position. When we break down those requests for proposals and the $9.3 million currently under contract, we haven’t really disclosed what the tests are.
We offer all of our commercial tests as part of our biopharmaceutical offering and then we offer a number of additional tests, both tests that we have created and offer for RUO use and just have chosen to not commercialize, but also we offer custom assay development. And so it really is a broad spectrum of different projects and tests or assays that we’re offering and the biopharmaceutical partners are really coming to us at varied stages of their own development and research. So, we feel like we’re fairly balanced. We’re also balanced, I’d say, across size of the biopharmaceutical companies, where we’ve got some small biopharmaceutical companies coming in along with some of the major more significant names that everybody might know. Is that helpful, Yuko?
Yuko Oku: Yes, that was great. Thank you so much Scott. Also, with the upcoming CHEST Conference, what presentation and presence do you anticipate to have there? It’s a conference that you are historically been present at. And then is it possible that we could see interim data from ALTITUDE at CHEST?
Scott Hutton: Yes. Great question. We look towards the annual CHEST meeting as one of the biggest opportunities for us. If you’re not familiar with it, it’s the largest Pulmonology Society — Physician Society Conference on an annual basis, usually held in October and November. This year’s meeting has been pulled up, so it’s early October. We’re not yet able to disclose exactly what will be presented and published as a number of the items that we’ve already had accepted are embargoed until we get closer to the event. And we’ve got a number of other efforts that are still in the works. We put a lot of pressure on ourselves to make certain that we show up, representing who we are. And so we think this CHEST will be equally as impactful as the last where we have an opportunity to get in front of a number of pulmonologists with an ever-increasing book of data.
